Catherine Hou
YOU?
Author Swipe
View article: The development of a PET radiotracer for imaging alpha synuclein aggregates in Parkinson's disease
The development of a PET radiotracer for imaging alpha synuclein aggregates in Parkinson's disease Open
An ultrahigh throughput in silico screen was conducted on 42 M compounds in the Mcule database and led to the identification of a new lead compound for radiotracer development for use with the imaging technique, positron emission tomograph…
View article: PB2 627V and HA 217 sites synergistically affect the lethality of H9N2 in mice
PB2 627V and HA 217 sites synergistically affect the lethality of H9N2 in mice Open
The H9N2 subtype avian influenza virus (AIV) continues to propagate and undergo evolution within China, thereby posing a significant threat to the poultry industry. This study encompassed the collection of 436 samples and swabs in East Chi…
View article: Topical indocyanine green antimicrobial photodynamic therapy for refractory feline chronic gingivostomatitis: A case report
Topical indocyanine green antimicrobial photodynamic therapy for refractory feline chronic gingivostomatitis: A case report Open
Feline chronic gingivostomatitis (FCGS) is a painful and severe inflammatory mucosal disease in cats that presents significant challenges in treatment. This case study describes a novel approach for a cat with FCGS that was unresponsive to…
View article: A Small-molecule Antagonist Radiotracer for Positron Emission Tomography Imaging of the Mu Opioid Receptor
A Small-molecule Antagonist Radiotracer for Positron Emission Tomography Imaging of the Mu Opioid Receptor Open
The opioid crisis is a catastrophic health emergency catalyzed by the misuse of opioids that target and activate the mu opioid receptor. Traditional radioligands used to study the mu opioid receptor are often tightly regulated owing to the…
View article: Positron Emission Tomography with [18F]ROStrace Reveals Progressive Elevations in Oxidative Stress in a Mouse Model of Alpha-Synucleinopathy
Positron Emission Tomography with [18F]ROStrace Reveals Progressive Elevations in Oxidative Stress in a Mouse Model of Alpha-Synucleinopathy Open
The synucleinopathies are a diverse group of neurodegenerative disorders characterized by the accumulation of aggregated alpha-synuclein (aSyn) in vulnerable populations of brain cells. Oxidative stress is both a cause and a consequence of…
View article: A Novel Brain PET Radiotracer for Imaging Alpha Synuclein Fibrils in Multiple System Atrophy
A Novel Brain PET Radiotracer for Imaging Alpha Synuclein Fibrils in Multiple System Atrophy Open
Abnormal α-synuclein (α-syn) aggregation characterizes α-synucleinopathies, including Parkinson's disease (PD) and multiple system atrophy (MSA). However, no suitable positron emission tomography (PET) radiotracer for imaging α-syn in PD a…
View article: Supplementary Figures 1-10; Supplemental Tables 1-6; and Supplemental Materials and Methods from Targeting PARP-1 with Alpha-Particles Is Potently Cytotoxic to Human Neuroblastoma in Preclinical Models
Supplementary Figures 1-10; Supplemental Tables 1-6; and Supplemental Materials and Methods from Targeting PARP-1 with Alpha-Particles Is Potently Cytotoxic to Human Neuroblastoma in Preclinical Models Open
SI Figure 1: Reaction scheme for synthesizing 1-(4-astatophenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one ([211At]MM4) from tin precursor 1-(4-(tributylstannyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; SI Figure…
View article: Data from Targeting PARP-1 with Alpha-Particles Is Potently Cytotoxic to Human Neuroblastoma in Preclinical Models
Data from Targeting PARP-1 with Alpha-Particles Is Potently Cytotoxic to Human Neuroblastoma in Preclinical Models Open
Alpha-emitters can be pharmacologically delivered for irradiation of single cancer cells, but cellular lethality could be further enhanced by targeting alpha-emitters directly to the nucleus. PARP-1 is a druggable protein in the nucleus th…
View article: Data from Targeting PARP-1 with Alpha-Particles Is Potently Cytotoxic to Human Neuroblastoma in Preclinical Models
Data from Targeting PARP-1 with Alpha-Particles Is Potently Cytotoxic to Human Neuroblastoma in Preclinical Models Open
Alpha-emitters can be pharmacologically delivered for irradiation of single cancer cells, but cellular lethality could be further enhanced by targeting alpha-emitters directly to the nucleus. PARP-1 is a druggable protein in the nucleus th…
View article: Supplementary Figures 1-10; Supplemental Tables 1-6; and Supplemental Materials and Methods from Targeting PARP-1 with Alpha-Particles Is Potently Cytotoxic to Human Neuroblastoma in Preclinical Models
Supplementary Figures 1-10; Supplemental Tables 1-6; and Supplemental Materials and Methods from Targeting PARP-1 with Alpha-Particles Is Potently Cytotoxic to Human Neuroblastoma in Preclinical Models Open
SI Figure 1: Reaction scheme for synthesizing 1-(4-astatophenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one ([211At]MM4) from tin precursor 1-(4-(tributylstannyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; SI Figure…
View article: Supplementary Data from Cell-Proliferation Imaging for Monitoring Response to CDK4/6 Inhibition Combined with Endocrine-Therapy in Breast Cancer: Comparison of [<sup>18</sup>F]FLT and [<sup>18</sup>F]ISO-1 PET/CT
Supplementary Data from Cell-Proliferation Imaging for Monitoring Response to CDK4/6 Inhibition Combined with Endocrine-Therapy in Breast Cancer: Comparison of [<sup>18</sup>F]FLT and [<sup>18</sup>F]ISO-1 PET/CT Open
Supplementary Tables and Figures
View article: Data from Cell-Proliferation Imaging for Monitoring Response to CDK4/6 Inhibition Combined with Endocrine-Therapy in Breast Cancer: Comparison of [<sup>18</sup>F]FLT and [<sup>18</sup>F]ISO-1 PET/CT
Data from Cell-Proliferation Imaging for Monitoring Response to CDK4/6 Inhibition Combined with Endocrine-Therapy in Breast Cancer: Comparison of [<sup>18</sup>F]FLT and [<sup>18</sup>F]ISO-1 PET/CT Open
Purpose:Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors in combination with endocrine-therapy have emerged as an important regimen of care for estrogen receptor (ER)-positive metastatic breast cancer, although identifying predictive biomar…
View article: Data from Preclinical Development of [<sup>211</sup>At]meta- astatobenzylguanidine ([<sup>211</sup>At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma
Data from Preclinical Development of [<sup>211</sup>At]meta- astatobenzylguanidine ([<sup>211</sup>At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma Open
Purpose:[131I]meta-iodobenzylguanidine ([131I]MIBG) is a targeted radiotherapeutic administered systemically to deliver beta particle radiation in neuroblastoma. However, relapses in the bone marrow are common. [211At]meta-astatobenzylguan…
View article: Supplementary Figure from Preclinical Development of [<sup>211</sup>At]meta- astatobenzylguanidine ([<sup>211</sup>At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma
Supplementary Figure from Preclinical Development of [<sup>211</sup>At]meta- astatobenzylguanidine ([<sup>211</sup>At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma Open
Supplementary Figure from Preclinical Development of [211At]meta- astatobenzylguanidine ([211At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma
View article: Supplementary Figure from Preclinical Development of [<sup>211</sup>At]meta- astatobenzylguanidine ([<sup>211</sup>At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma
Supplementary Figure from Preclinical Development of [<sup>211</sup>At]meta- astatobenzylguanidine ([<sup>211</sup>At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma Open
Supplementary Figure from Preclinical Development of [211At]meta- astatobenzylguanidine ([211At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma
View article: Supplementary Figure from Preclinical Development of [<sup>211</sup>At]meta- astatobenzylguanidine ([<sup>211</sup>At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma
Supplementary Figure from Preclinical Development of [<sup>211</sup>At]meta- astatobenzylguanidine ([<sup>211</sup>At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma Open
Supplementary Figure from Preclinical Development of [211At]meta- astatobenzylguanidine ([211At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma
View article: Supplementary Data from Cell-Proliferation Imaging for Monitoring Response to CDK4/6 Inhibition Combined with Endocrine-Therapy in Breast Cancer: Comparison of [<sup>18</sup>F]FLT and [<sup>18</sup>F]ISO-1 PET/CT
Supplementary Data from Cell-Proliferation Imaging for Monitoring Response to CDK4/6 Inhibition Combined with Endocrine-Therapy in Breast Cancer: Comparison of [<sup>18</sup>F]FLT and [<sup>18</sup>F]ISO-1 PET/CT Open
Supplementary Tables and Figures
View article: Data from Cell-Proliferation Imaging for Monitoring Response to CDK4/6 Inhibition Combined with Endocrine-Therapy in Breast Cancer: Comparison of [<sup>18</sup>F]FLT and [<sup>18</sup>F]ISO-1 PET/CT
Data from Cell-Proliferation Imaging for Monitoring Response to CDK4/6 Inhibition Combined with Endocrine-Therapy in Breast Cancer: Comparison of [<sup>18</sup>F]FLT and [<sup>18</sup>F]ISO-1 PET/CT Open
Purpose:Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors in combination with endocrine-therapy have emerged as an important regimen of care for estrogen receptor (ER)-positive metastatic breast cancer, although identifying predictive biomar…
View article: Supplementary Figure from Preclinical Development of [<sup>211</sup>At]meta- astatobenzylguanidine ([<sup>211</sup>At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma
Supplementary Figure from Preclinical Development of [<sup>211</sup>At]meta- astatobenzylguanidine ([<sup>211</sup>At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma Open
Supplementary Figure from Preclinical Development of [211At]meta- astatobenzylguanidine ([211At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma
View article: Data from Preclinical Development of [<sup>211</sup>At]meta- astatobenzylguanidine ([<sup>211</sup>At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma
Data from Preclinical Development of [<sup>211</sup>At]meta- astatobenzylguanidine ([<sup>211</sup>At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma Open
Purpose:[131I]meta-iodobenzylguanidine ([131I]MIBG) is a targeted radiotherapeutic administered systemically to deliver beta particle radiation in neuroblastoma. However, relapses in the bone marrow are common. [211At]meta-astatobenzylguan…
View article: Supplementary Figure from Preclinical Development of [<sup>211</sup>At]meta- astatobenzylguanidine ([<sup>211</sup>At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma
Supplementary Figure from Preclinical Development of [<sup>211</sup>At]meta- astatobenzylguanidine ([<sup>211</sup>At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma Open
Supplementary Figure from Preclinical Development of [211At]meta- astatobenzylguanidine ([211At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma
View article: Supplementary Figure from Preclinical Development of [<sup>211</sup>At]meta- astatobenzylguanidine ([<sup>211</sup>At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma
Supplementary Figure from Preclinical Development of [<sup>211</sup>At]meta- astatobenzylguanidine ([<sup>211</sup>At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma Open
Supplementary Figure from Preclinical Development of [211At]meta- astatobenzylguanidine ([211At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma
View article: Supplementary Figure from Preclinical Development of [<sup>211</sup>At]meta- astatobenzylguanidine ([<sup>211</sup>At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma
Supplementary Figure from Preclinical Development of [<sup>211</sup>At]meta- astatobenzylguanidine ([<sup>211</sup>At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma Open
Supplementary Figure from Preclinical Development of [211At]meta- astatobenzylguanidine ([211At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma
View article: Supplementary Figure from Preclinical Development of [<sup>211</sup>At]meta- astatobenzylguanidine ([<sup>211</sup>At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma
Supplementary Figure from Preclinical Development of [<sup>211</sup>At]meta- astatobenzylguanidine ([<sup>211</sup>At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma Open
Supplementary Figure from Preclinical Development of [211At]meta- astatobenzylguanidine ([211At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma
View article: Supplementary Figure from Preclinical Development of [<sup>211</sup>At]meta- astatobenzylguanidine ([<sup>211</sup>At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma
Supplementary Figure from Preclinical Development of [<sup>211</sup>At]meta- astatobenzylguanidine ([<sup>211</sup>At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma Open
Supplementary Figure from Preclinical Development of [211At]meta- astatobenzylguanidine ([211At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma
View article: Supplementary Figure from Preclinical Development of [<sup>211</sup>At]meta- astatobenzylguanidine ([<sup>211</sup>At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma
Supplementary Figure from Preclinical Development of [<sup>211</sup>At]meta- astatobenzylguanidine ([<sup>211</sup>At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma Open
Supplementary Figure from Preclinical Development of [211At]meta- astatobenzylguanidine ([211At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma